A disruptive multi-sensor chip for fast and effective management of Sepsis at the point of Care

Project Information

SepsiCare

Grant agreement ID: 888337

DOI

10.3030/888337

Project closed

EC signature date 2 December 2019

Start date 1 January 2020

End date 31 August 2020

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

BIALOOM LTD
Cyprus

Periodic Reporting for period 1 - SepsiCare (A disruptive multi-sensor chip for fast and effective management of Sepsis at the point of Care)

Reporting period: 2020-01-01 to 2020-08-31

Summary of the context and overall objectives of the project

The project focuses on the use of novel photonic biosensing technology used to accelerate the diagnosis and treatment of severe bacterial infections next to the patient. The solution relies on a novel photonic integrated biochip that is capable to measure a set of key patient-condition indicators to the clinician from small volumes of patient blood in order to accelerate sepsis diagnosis, monitor disease progression and assess the effects of treatment within minutes. This feasibility study revealed that sepsicare is looking at the right direction and a deeper understanding of the market needs, specifications and challenges had to be implemented. With this study a major market opportunity was verified in point of care diagnostics in the Emergency Room (ER) and Intensive Care Units (ICU) of Hospitals and the project will continue pursuing further development financing.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

In summary the project focused in three main activities.
Task 1 performed a market survey and analysis, end user studies through interviews and communication with key stakeholders, as well as a preliminary review of directives and regulatory requirements.
Task 2 involved a technical feasibility study based on the market analysis results.
Task 3 focused on the generation of an elaborate business plan. The initial business plan was updated to include a detailed marketing, dissemination and commercialization plan, a verified USP, pricing strategies, IPR and a financial plan resulting in the maximum permissible resources to bring the product into the market.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Sepsicare aims to bring a new solution to the market for addressing the global unmet need for fast diagnosis and therapy of acute infections and sepsis with clear socioeconomic impact. More specifically, sepsis affects more than 30 million people worldwide each year translating into healthcare yearly costs nearly $60 billion in the US alone. Starting appropriate and effective antimicrobial treatment is crucial for sepsis survival. Achieving an early and accurate diagnosis is a prerequisite for rapid and successful antibiotic therapy. However, point of care (POC) solutions for fast, affordable and effective management of sepsis remains a challenge. The impact of this unmet clinical need to the hospitals relates to the increased time & cost of patient hospitalization. For patients, this has an impact on increased mortality and morbidity (1 in 3 patients of sepsis die) resulting from suboptimal treatment of bacterial infections.